As global health officials scramble to contain antimicrobial resistance, a new study finds that hundreds of drug makers continue to manufacture and sell numerous unapproved formulations in India, which is only likely to exacerbate concerns the problem will worsen.

Of 118 different formulations of fixed-dose combination antibiotics sold in India between 2007 and 2012, the researchers found that 64 percent were not approved by the national drugs regulator, the Central Drugs Standard Control Organization, even though the sale of unapproved new medicines is illegal in India. By contrast, only five of the formulations were approved in the U.K. or U.S.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy